These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 23271750)

  • 1. Eli Lilly settles corrupt foreign practices complaint for $29.4m.
    Roehr B
    BMJ; 2012 Dec; 345():e8694. PubMed ID: 23271750
    [No Abstract]   [Full Text] [Related]  

  • 2. Merck pays $1bn penalty in relation to promotion of rofecoxib.
    Tanne JH
    BMJ; 2011 Nov; 343():d7702. PubMed ID: 22123916
    [No Abstract]   [Full Text] [Related]  

  • 3. Novo Nordisk pays $58.7m to settle claims of mis-selling liraglutide.
    Dyer O
    BMJ; 2017 Sep; 358():j4214. PubMed ID: 28887314
    [No Abstract]   [Full Text] [Related]  

  • 4. Attorney abuses of Daubert hearings: junk science, junk law, or just plain obstruction?
    Gutheil TG; Bursztajn HJ
    J Am Acad Psychiatry Law; 2005; 33(2):150-2. PubMed ID: 15985655
    [No Abstract]   [Full Text] [Related]  

  • 5. Former drug execs lose appeal. Bid for re-entry to Medicare is denied.
    Rhea S
    Mod Healthc; 2010 Dec 20-27; 40(51):14. PubMed ID: 21344720
    [No Abstract]   [Full Text] [Related]  

  • 6. Eli Lilly: correction and apology.
    BMJ; 2005 Jan; 330(7485):211. PubMed ID: 15677638
    [No Abstract]   [Full Text] [Related]  

  • 7. UK response to serial drug company misdemeanour-no action, no shame.
    Braillon A; Noble JH; Bewley S
    BMJ; 2016 Jul; 354():i4022. PubMed ID: 28114094
    [No Abstract]   [Full Text] [Related]  

  • 8. Eli Lilly pays record $1.4bn for promoting off-label use of olanzapine.
    Kmietowicz Z
    BMJ; 2009 Jan; 338():b217. PubMed ID: 19155260
    [No Abstract]   [Full Text] [Related]  

  • 9. Medical Council of India orders doctors' suspension for drug industry junket.
    Mudur G
    BMJ; 2015 Feb; 350():h1106. PubMed ID: 25721684
    [No Abstract]   [Full Text] [Related]  

  • 10. GSK's head of finance in China is banned from leaving the country.
    Parry J
    BMJ; 2013 Jul; 347():f4691. PubMed ID: 23881949
    [No Abstract]   [Full Text] [Related]  

  • 11. Eli Lilly enters venture capital arena.
    Fletcher L
    Nat Biotechnol; 2001 Nov; 19(11):997-8. PubMed ID: 11689830
    [No Abstract]   [Full Text] [Related]  

  • 12. Lilly purchase of PCS awaits FTC clearance.
    Scott L
    Mod Healthc; 1994 Oct; 24(44):29. PubMed ID: 10138146
    [No Abstract]   [Full Text] [Related]  

  • 13. Eli Lilly agrees to acquire Novartis Animal Health.
    Vet Rec; 2014 Apr; 174(17):417. PubMed ID: 24769763
    [No Abstract]   [Full Text] [Related]  

  • 14. Lilly deal's timing drew FTC notice.
    Scott L
    Mod Healthc; 1994 Oct; 24(43):8. PubMed ID: 10138136
    [No Abstract]   [Full Text] [Related]  

  • 15. Resident and fellow section. Conflicts of interest between physicians and the pharmaceutical industry: focus on headache medicine.
    Rubin EB; Bernat JL
    Headache; 2008; 48(10):1545-9. PubMed ID: 19076654
    [No Abstract]   [Full Text] [Related]  

  • 16. Paediatricians and the pharmaceutical industry: an industry perspective of the challenges ahead.
    Leather DA; Davis SC
    Paediatr Respir Rev; 2006 Mar; 7(1):60-6. PubMed ID: 16473819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novartis must face kickback lawsuit over "sham" speaker events.
    McCarthy M
    BMJ; 2014 Oct; 349():g6044. PubMed ID: 25288583
    [No Abstract]   [Full Text] [Related]  

  • 18. Encouraging further innovation: Ariad v. Eli Lilly and the written description requirement.
    Jakas J
    Seton Hall Law Rev; 2012; 42(3):1287-36. PubMed ID: 22803220
    [No Abstract]   [Full Text] [Related]  

  • 19. Entrepreneurship in the medical academy: possibilities and challenges in commercialization of research discoveries.
    Loscalzo J
    Circulation; 2007 Mar; 115(12):1504-7. PubMed ID: 17389277
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of drug industry marketing practices on formularies questioned by federal agencies.
    Gatty B
    Hosp Formul; 1994 Nov; 29(11):786, 785. PubMed ID: 10138576
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.